BCC 2023 | ADCs: is chemotherapy dead?

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, discusses the role of ADCs (antibody-drug conjugates) in the management of HR+ breast cancer. Dr. Ciruelos provides an overview of ADCs, which are targeted therapies that combine the specificity of monoclonal antibodies with the cytotoxicity of chemotherapy. She also highlights some of the key clinical trials that have evaluated the efficacy and safety of ADCs in HR+ breast cancer, including the recent results of trials evaluating trastuzumab deruxtecan. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.